HK1254398A1 - 納米粒子組合物的生物標誌物 - Google Patents

納米粒子組合物的生物標誌物 Download PDF

Info

Publication number
HK1254398A1
HK1254398A1 HK18113475.7A HK18113475A HK1254398A1 HK 1254398 A1 HK1254398 A1 HK 1254398A1 HK 18113475 A HK18113475 A HK 18113475A HK 1254398 A1 HK1254398 A1 HK 1254398A1
Authority
HK
Hong Kong
Prior art keywords
biomarkers
nanoparticle compositions
mtor
compositions
restenosis
Prior art date
Application number
HK18113475.7A
Other languages
English (en)
Chinese (zh)
Inventor
Neil P. Desai
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of HK1254398A1 publication Critical patent/HK1254398A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18113475.7A 2015-06-29 2016-06-29 納米粒子組合物的生物標誌物 HK1254398A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
US62/186,309 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions

Publications (1)

Publication Number Publication Date
HK1254398A1 true HK1254398A1 (zh) 2019-07-19

Family

ID=57609078

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113475.7A HK1254398A1 (zh) 2015-06-29 2016-06-29 納米粒子組合物的生物標誌物

Country Status (10)

Country Link
US (3) US20180177771A1 (enExample)
EP (1) EP3313381A4 (enExample)
JP (4) JP2018527308A (enExample)
KR (2) KR20240144442A (enExample)
AU (3) AU2016285727B9 (enExample)
CA (1) CA2990703C (enExample)
HK (1) HK1254398A1 (enExample)
IL (2) IL312318A (enExample)
MX (2) MX2017016519A (enExample)
WO (1) WO2017004264A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス, エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
EP3768268A4 (en) * 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
KR20210024471A (ko) * 2018-05-22 2021-03-05 아브락시스 바이오사이언스, 엘엘씨 폐고혈압을 치료하기 위한 방법 및 조성물
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
CN120267635A (zh) * 2019-03-19 2025-07-08 阿布拉科斯生物科学有限公司 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
MX2022005715A (es) * 2019-11-11 2022-09-19 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
AU2021358768A1 (en) * 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
KR20190002733A (ko) * 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP2968191B1 (en) * 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
EP2971122B1 (en) * 2013-03-15 2020-08-26 Memorial Sloan Kettering Cancer Center Biomarkers for response to rapamycin analogs
US20180153863A1 (en) * 2015-06-29 2018-06-07 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy

Also Published As

Publication number Publication date
IL256326B1 (en) 2024-05-01
IL312318A (en) 2024-06-01
IL256326B2 (en) 2024-09-01
US20250152563A1 (en) 2025-05-15
CA2990703C (en) 2024-04-30
KR20240144442A (ko) 2024-10-02
CA2990703A1 (en) 2017-01-05
EP3313381A4 (en) 2019-02-27
US20230080409A1 (en) 2023-03-16
WO2017004264A1 (en) 2017-01-05
KR102708679B1 (ko) 2024-09-24
AU2024204661A1 (en) 2024-07-25
MX2017016519A (es) 2018-08-16
AU2016285727B9 (en) 2021-09-30
MX2023013010A (es) 2023-11-15
IL256326A (en) 2018-02-28
AU2016285727A1 (en) 2018-02-01
US20180177771A1 (en) 2018-06-28
JP2018527308A (ja) 2018-09-20
KR20180019230A (ko) 2018-02-23
AU2021290200B2 (en) 2024-05-02
EP3313381A1 (en) 2018-05-02
JP2023071656A (ja) 2023-05-23
AU2021290200A1 (en) 2022-01-20
AU2016285727B2 (en) 2021-09-23
JP2025097987A (ja) 2025-07-01
JP2021169457A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
HK1254398A1 (zh) 納米粒子組合物的生物標誌物
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
HK1220405A1 (zh) 治疗膀胱癌的方法
HK1247093A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
MX2023012080A (es) Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y sus usos en el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr).
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
IL272844A (en) Compounds, preparations and methods for the treatment or prevention of cancers resistant to HER-motor drugs
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
HK1255163A1 (zh) 作为apj受体激动剂的杂芳基羟基嘧啶酮
MX2015011752A (es) Metodos para tratar cancer de pulmon.
WO2015120062A3 (en) Therapeutic compounds and compositions
WO2016167944A3 (en) Compositions and methods for treating autism
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
EA202191471A1 (ru) Противовоспалительные полипептиды
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
WO2016036960A8 (en) Therapeutic nanoparticles and related compositions, methods and systems
WO2017127706A8 (en) Compositions and methods for inhibiting dkk-1
WO2017095950A3 (en) Compounds for treating proliferative diseases
NZ733451A (en) Combination therapy for pulmonary hypertension
TW201612342A (en) Sputtering target, optical functional film and layered wiring film
WO2015175884A3 (en) Compositions and methods for treating and preventing pancreatitis, renal injury and cancer